NASDAQ: BBNXBeta Bionics Inc Stock
$26.78-0.01 (-0.04%)
Updated Oct 30, 2025
BBNX Price
$26.78
Fair Value Price
N/A
Market Cap
$1.18B
52 Week Low
$8.89
52 Week High
$30.47
P/E
-6.1x
P/B
4x
P/S
9.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$88.57M
Earnings
-$77.84M
Gross Margin
54.5%
Operating Margin
-87.89%
Profit Margin
-87.9%
Debt to Equity
0.12
Operating Cash Flow
-$57M
Beta
1.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BBNX Overview
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BBNX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BBNX news, forecast changes, insider trades & much more!
BBNX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BBNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BBNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BBNX is poor value based on its book value relative to its share price (4x), compared to the US Medical Devices industry average (3.91x)
P/B vs Industry Valuation
BBNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BBNX due diligence checks available for Premium users.
Valuation
BBNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.1x
Industry
28.38x
Market
40.85x
BBNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4x
Industry
3.91x
BBNX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BBNX's financial health
Profit margin
Revenue
$27.3M
Net Income
-$14.2M
Profit Margin
-52.1%
BBNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BBNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$330.0M
Liabilities
$35.3M
Debt to equity
0.12
BBNX's short-term assets ($270.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBNX's short-term assets ($270.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.7M
Investing
$9.5M
Financing
$2.7M
BBNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BBNX vs Medical Device Stocks
Beta Bionics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.